Navigation Links
Regeneron's Eylea Now Captures One-Quarter Of Wet AMD Patient Share, Surpassing Share Of Roche/Genentech's Lucentis

EXTON, Penn., Aug. 15, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed retinal specialists/general ophthalmologists now treat 26 percent of their intravitreal pharmaceutically treated wet age-related macular degeneration (AMD) patients with Regeneron's Eylea, a significant increase from one year ago. Eylea has been on the market since November 2011. In fact, patient share for Eylea now surpasses that for Roche/Genentech's Lucentis (21 percent), which has been available since 2006. However, off-label use of Roche/Genentech's Avastin continues to dominate the wet AMD market, largely due to its low cost relative to the other anti-vascular endothelial growth factor (VEGF) agents and proven efficacy.

According to the TreatmentTrends®: Dry/Wet AMD (US) report, physician preference for Eylea is likely driven by its convenient twice monthly dosing frequency, which is supported by the finding that wet AMD patients receive significantly fewer Eylea injections than Avastin or Lucentis injections during the first two years of treatment. Data from the report also suggest that Eylea is moving up in the wet AMD treatment algorithm and is now the most preferred branded therapy indicated for the treatment of wet AMD, with Lucentis being the typical third-line treatment option.

"This shift in Eylea use is likely motivated by prescribers' high satisfaction with the agent and their positive perceptions related to its efficacy," said BioTrends Research Group Senior Business Insights Analyst Emma Williams, Ph.D. "These perceptions will contribute to the continued growth of Eylea patient share over the next six months and will trail only Avastin's patient share."

Report findings also reveal that surveyed physicians rate geographic atrophy associated with dry AMD as the AMD disease type with the greatest need for new products, a finding which is not surprising given the high degree of vision loss suffered by these patients and the paucity of treatment options currently available for dry AMD. However, even as physicians acknowledge the high unmet need for dry AMD, few are aware of products in development for dry AMD, including Otsuka/Acucela's ACU-4429 and MacuCLEAR's MC-1101. Instead, awareness is higher for surveyed products in development for wet AMD, in particular Ophthotech's Fovista, Ohr Pharmaceuticals's squalamine and Allergan's anti-VEGF DARPin. Surveyed physicians perceive these products for wet AMD as having potential to provide the most value to the treatment of their AMD patients, largely due to Fovista's synergistic effect when administered with an anti-VEGF agent, squalamine's eye drop formulation and anti-VEGF DARPin's novel mechanism of action and duration of action.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Watching, Reading and Listening: A New Way to Interact with Patient Information
5. Phreesia identifies over 26% of patients who require additional autism evaluation
6. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
10. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
11. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
Post Your Comments:
(Date:10/13/2015)... World Thrombosis Day Interactive Infographic ...   --> World Thrombosis Day Interactive ... promote vital global awareness of thrombosis, its causes, ... the formation of potentially deadly blood clots in ... thromboembolism (VTE) - or the artery (arterial thrombosis) [1] ...
(Date:10/12/2015)... the United States . By early next year, ... the United States . By early next year, ... The University of Texas MD Anderson Cancer Center, Elekta and ... Tesla) MRI-guided linear accelerator in the United States ... a non-clinical capacity. Royal Philips (NYSE: PHG ...
(Date:10/12/2015)... , Oct. 12, 2015 ... the setbacks and the needs of the medical membrane ... of membrane devices within the different medical membrane devices ... blood microfilters/apheresis systems and membrane diagnostic devices. - Gain ... in this market. --> Use this report ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... ... Anik Singal's newly launched "Publish Academy" training course . Singal's new program, ... for enrollment today, and marketers around the Internet are weighing in with reviews. ...
(Date:10/13/2015)... ... 2015 , ... Scientists in Seattle and Vancouver compared the diagnostic value of ... mesothelioma. Surviving Mesothelioma has just posted an article on the new research. Click ... and the University of British Columbia found that certain genetic alterations were seen just ...
(Date:10/13/2015)... ... October 13, 2015 , ... California Southern ... Nursing. Dr. McLeod—who earned her Doctor of Nursing Practice from the renowned Johns ... spanned four decades. , Dr. McLeod’s long and successful nursing practice included a ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... most people do not breathe correctly. According to T’ai Chi (also spelled “Taiji”) ... learning to breathe correctly, in concert with the 7,000 year old tradition they ...
(Date:10/13/2015)... ... October 13, 2015 , ... In an ongoing ... PediaPlex , a Southlake, Texas, child development and pediatric therapy center, is working ... military families about their options for receiving this kind of care for affected ...
Breaking Medicine News(10 mins):